ICYMI: FDA Approves IVIG in Dermatomyositis https://t.co/BZsl8a6ArW The FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/VFF0QMqbin

• https://bit.ly/3iuXHU1

Fracture Risk with Low Dose Steroid https://t.co/HcYpx8IDcB A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures. https://t.co/1bc5nyZUzG

• https://bit.ly/3eJ3ZOQ

Tofacitinib Efficacy in Ankylosing Spondylitis https://t.co/SEKa5OnB50 Deodhar and colleagues have published the results of a study showing that in adult patients with active ankylosing spondylitis (AS), oral tofacitinib was effective (versus placebo) and safe. https://t.co/Wb19EJQZHN

• https://bit.ly/3xZbB7t

Growing Cannabis Use in Arthritis Patients The National Databank for Rheumatic Diseases reports a significant increased in cannabis use amongst arthritis patients between 2014-2019. https://t.co/9YyYB75GuN https://t.co/Xs24kBLmeg

• https://bit.ly/36WuXhE

New-Onset IBD and IL-17 Inhibitors: What Is the Risk? https://t.co/zXDQotDiWV Patients w/ inflammatory/autoimmune diseases who initiated treatment w/ IL-17 inhibitors didnt have a higher risk for development of IBD, but only based on the severity of their underlying disease https://t.co/hbWf45pQWt

• https://bit.ly/3eHmuTJ

Steroid (GC) withdrawal studied in T2T RA cohort of 207 RA pts (F/U 39 mos); Only 60% discontinued GC, w/ low risk of flare. BUT D/Cs were SLOW w/ only 9.7%, 26.6%, 48.0% & 58.6% at 6 mos, 1, 2 & 3 yrs - median time to cessation = 27 mos https://t.co/h02aueYKwN

• https://bit.ly/2UCX1E4

COAST-Y - an extension study of 155 spondyloarthritis pts in remission on ixekizumab; they either continue or had IXE withdrawn. After 40 weeks, 83% on IXE vs 55% of PBO (WD) pts remained flare free. Most flares >20 wks of IXE withdrawal https://t.co/DDzCoFxt0d https://t.co/jgTxFCgQIq

• https://bit.ly/3iFmtAK

Retrospective cohort study of 1719 Psoriasis only pts (F/U 14721 py) were Rx w/ topicals (81%), cDMARDs (13%), bDMARDs (6%). Overall, 239 patients (14%) developed PsA - Lower risk of PSA if Rx w/ biologics (IRR=0.26 vs topicals; not csDMARDs) https://t.co/BqJWPxG7xf

• https://bit.ly/3kNgTiC

Metanalysis of Tramadol efficacy & safety in knee or hip #OA. 6 RCTs (3,611 pts) showed little clinical benefit w/ 100/d or 200 mg/d; only 300mg/d was better vs PBO at pain & functional improvement. All doses had higher risk of GI, CNS AEs & W/D https://t.co/wDLHFQWFOe

• https://bit.ly/3rAoVfZ

While myeloperoxidase (MPO) Abs are seen in idiopathic pulmonary fibrosis (IPF), only 7–23% develop vasculitis. Study of 58 pts w/ IPF & MPO Abs - UIP most frequent ILD pattern, 13 had rheumatic dz; MPO Abs did not change survival of UIP/IPF pts https://t.co/RXXIPUBMBT https://t.co/v3KhEaefZD

• https://bit.ly/3BnPfhQ

Anti- neutrophil extracellular traps (NET) Abs were elevated in 328 COVID-19 pts, 27% IgG & 60% IgM. Net Abs assoc w/ circulating NETs, impaired O2 ventilation, high D-dimers. They likely impair NET clearance and may worsen thromboinflammation. https://t.co/xRNKqKjxzS

• https://bit.ly/3ivqsQo